Podcasts about Clinical

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are dismayed by the changes on CDC vaccine website positively stating the link between autism and vaccination, the finding of wild type poliovirus 1 in Germany, Marburg virus in Ethiopia, decimation of the elephant breeding colony by H5N1 and the first human case of H5N5 influenza virus infection before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, antibody escape by seasonal flu viruses, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, if resistance exercise aids in recovery from long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Autism and Vaccines (CDC: Vaccine Safety) A new road to eradication- WPV 1 in Germany from Afghanistan (Reuters) Ethiopia confirms first outbreak of Marburg virus disease (WHO: Ethiopia) Highly Pathogenic Avian Influenza Viruses (HPAIV) Associated with Major Southern Elephant Seal Decline at South Georgia (Communications Biology) Avian flu has decimated world's largest breeding colony of southern elephant seals (CIDRAP) Washington resident is infected with a different type of bird flu (AP News) Pelagic Seabirds (OceanAminals) That sounds far away: Multiple transatlantic incursions of highly pathogenic avian influenza clade 2.3.4.4b A(H5N5) virus into North America and spillover to mammals (Cell Reports) Regional voices, different choices: Parents' and caregivers' HPV vaccine attitudes in the northeast and Southeast United States (Vaccine) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Emergence of seasonal influenza A(H3N2) variants with immune escape potential warrants enhanced molecular and epidemiological surveillance for the 2025–2026 season (University of Toronto Press) Types of Influenza Viruses (CDC: Influenza (flu)) With an absent CDC and mismatched 'subclade K' flu strain, experts face upcoming season with uncertainty (CIDRAP) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season(FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-word global database (Journal of Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease (CID) FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy: FDA Safety Communication (FDA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) COVID-19 vaccination is associated with reduced complications in pediatric patients with atopic dermatitis (Annals of Allergy, Asthma and Immunology) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) Risk mitigation of shared room ventilation and filtration on SARS-CoV-2 transmission: a multicenter test-negative study (Infection Control and Hospital Epidemiology) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Resistance Exercise Therapy After COVID-19 Infection(JAMA Open Network) Reaching out to US house representative Letters read on TWiV 1272 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

John Murray & Ali Bruce-Ball are joined by Jonathan Agnew to discuss commentating on cricket. He talks about his journey from lorry driver to broadcaster. Aggers reveals how much prep he does and his commentary top tips. And suggestions always welcome for our Great Glossary of Football Commentary and unintended pub names from commentary - WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk03:55 Jonathan Agnew joins the pod 08:45 From archery & dressage to Ben Stokes in 2019 12:45 What prep Aggers does for cricket? 18:00 From lorry driver to broadcaster 23:10 Aggers' Ashes memories down under 32:00 How to follow the Ashes on the BBC 35:25 Unintended pub names 39:30 Jonathan's favourite commentators' view 45:25 Great Glossary of Football Commentary 55:30 Jonathan on commentating on a replay!5 Live / BBC Sounds Premier League commentaries: Sat 1500 Liverpool v Forest, Sat 1500 Fulham v Sunderland on Sports Extra, Sat 1730 Newcastle v Man City, Sun 1400 Leeds v Aston Villa, Sun 1630 Arsenal v Tottenham, Tue 2000 Chelsea v Barcelona, Tue 2000 Man City v Bayer Leverkusen on Sports Extra, Wed 2000 Arsenal v Bayern Munich, Wed 2000 PSG v Tottenham on Sports Extra,Glossary so far (in alphabetical order):DIVISION ONE Bosman, Couldn't sort their feet out, Cruyff Turn, Dead-ball specialist, Fox in the box, Giving the goalkeeper the eyes, Head tennis, Hibs it, In a good moment, Johnny on the spot, The Maradona, Olimpico, Onion bag, Panenka, Rabona, Scorpion kick, Spursy, Tiki-taka, Where the kookaburra sleeps, Where the owl sleeps, Where the spiders sleep.DIVISION TWO Ball stays hit, Business end, Came down with snow on it, Catching practice, Cauldron atmosphere Coat is on a shoogly peg, Come back to haunt them, Corridor of uncertainty, Easy tap-in, Daisy-cutter, First cab off the rank, Good leave, Has that in his locker, High wide and not very handsome, Howler, Leading the line, Nutmeg, One for the cameras, One for the purists, Played us off the park, Purple patch, Put their laces through it, Rolls Royce, Root and branch review, Row Z, Screamer, Seats on the plane, Show across the bows, Stramash, Taking one for the team, That's great… (football), Thunderous strike.UNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Bread and butter, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.

In this episode, Sam Ashoo, MD and T.R. Eckler, MD discuss the November 2025 Emergency Medicine Practice article, Diagnosis and Management of Emergency Department Patients With Alcohol Withdrawal SyndromeEpidemiology & Background Rising ED visits related to alcohol use. Mortality rates and spectrum of patient presentations. Importance of high suspicion and complexity of cases.Pathophysiology & Mechanisms Alcohol metabolism and neurochemical changes. Differential diagnosis: Conditions that mimic alcohol withdrawal.Prehospital & EMS Considerations Role of EMS in triage and initial management. Use of sobering centers vs. ED transport. Prehospital administration of benzodiazepines (IM midazolam).History & Risk Assessment Key questions to assess risk for alcohol withdrawal syndrome. Importance of patient history, medication use, and comorbidities. Discussion on patient honesty and rapport.Physical Exam & Scoring Systems DSM-5 criteria for alcohol withdrawal. Use of CIWA-AR, BAWS, and PAWSS scoring systems. Importance of objective measurement for monitoring and disposition.Complications & Special PresentationsComplicated alcohol withdrawal: Hallucinosis, seizures, delirium tremens. Diagnostic workup: Labs, imaging, and co-ingestions. Special populations: End-stage liver disease, pregnancy, intubated patients.Treatment Strategies Mainstay: Benzodiazepines (types, dosing, and protocols). Phenobarbital: Indications, dosing, and evidence. Adjunctive therapies: Thiamine, glucose, magnesium. Alternative/adjunct medications: Gabapentin, ketamine, dexmedetomidine, baclofen.Clinical Pearls & Practice Changes Early, aggressive therapy to prevent complications. Symptom-based vs. fixed-schedule treatment. Gabapentin as an alternative or adjunct. Anti-craving medications for relapse prevention.Disposition & Protocols Use of scoring systems for safe discharge, observation, or admission. Importance of protocolized approaches and community resources.Summary & Take-Home Points Five key practice-changing points. Clinical pathway.Emergency Medicine Residents, get your free subscription by writing resident@ebmedicine.net

Clinical trial design in nephrology is evolving. In this episode, leading experts explore why a paradigm shift is needed from traditional biomarkers to patient-centered outcomes and practical strategies for advancing trial implementation. This conversation draws on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024) where clinicians, trialists, patient partners, regulators and industry scientists came together to rethink trial endpoints, outcomes and designs. Together, they discuss how reimagining kidney trials can generate more relevant, equitable, and actionable evidence for better kidney care worldwide. ParticipantsAdeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. Jennifer Lees Senior Clinical Lecturer and Honorary Consultant Nephrologist at the University of Glasgow, UK. Dr. Lees' research focuses on improving patient outcomes in kidney disease through better trial design, biomarker evaluation, and translational approaches linking research to clinical care. Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International.

Gender reveal celebrations have become more popular than ever. Whether it's cutting into a cake or popping a balloon, everyone waits for that exciting moment to see pink or blue. But, what happens when the color revealed isn't the one someone was hoping for?And is it okay to feel disappointed to not have the gender you hoped for?Joining guest host Anna Daly to discuss is Clinical and Health Psychologist, Dr Bronagh Fitzpatrick, Columnist with the Irish Independent, Tanya Sweeney, Editor of Cork Beo, Joe O'Shea and Lisa O'Sullivan Shaw (@modernirishmom on Instagram).

Step outside the operating room with us to explore the art, creativity, and humanism that shape a surgeon's life beyond medicine. Our guest Dr. Adnan Alseidi is not only a renowned hepatobiliary surgeon and surgical educator, but also an avid diver, photographer, and chef. Dr. Alseidi takes us from World War 2 shipwrecks to his restaurants around the world, reflecting on the fragility of humanity revealed in the oceans and moments of connection simmering in the kitchen. Along the way, he shares how creativity, service, and humility fuel his passions and his practice. Join hosts Pooja Varman, MD, Judith French, PhD, and Jeremy Lipman, MD, MHPE, for this inspiring conversation about finding joy and connection in and beyond surgical practice. Learning Objectives By the end of this episode, listeners will be able to  1.     Describe the ways in which creative pursuits can deepen a surgeon's perspective on medicine and life. 2.     Identify parallels between artistry and surgery, including precision, patience, and respect for human fragility. 3.     Discuss strategies for maintaining balance and encouraging trainees to integrate creativity into their professional identities. References 1.     Executive Leadership Program in Health Policy and Management at Brandeis University, sponsored by the American College of Surgeons and several co-sponsoring organizations. 2.     The Book of Joy, by Dalai Lama, Desmond Tutu, and Douglas Carlton Abrams 3.     Dr. Alseidi's Wildlife Photography Sponsor Disclaimer: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this week's episode of The Energy Code, Dr. Mike Belkowski takes listeners on a fascinating deep-dive into the origins, science, and cutting-edge clinical research behind deuterium-depleted water (DDW) — specifically Litewater, the most depleted DDW on the planet at just 10 ppm.   Drawing from a decades-long historical arc, from the Big Bang to Soviet gerontology labs to modern mitochondrial biochemistry, Dr. Mike breaks down how deuterium impacts ATP production, aging, longevity, cancer metabolism, and cellular repair. He also explains why deuterium depletion may be one of the strongest yet overlooked tools for increasing mitochondrial function and long-term resilience.   Listeners also get a rare behind-the-scenes look at Victor Sagalovsky's A Brief History of Deuterium-Depleted Water and the scientific breakthroughs that shaped the modern DDW field. Dr. Mike shares how BioLight's updated BioBlue formulas now use 100% Litewater, and why lowering deuterium levels below 120 ppm may be a cornerstone of anti-aging protocols. In This Episode, Dr. Belkowski Covers:  

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent news about Protecting Access to Medicare Act (PAMA) reform. Then, Dr. Pritt welcomes Trish Simner, Ph.D., a clinical microbiologist at Mayo Clinic, for an in-depth conversation about metagenomics. PAMA reform update and new RESULTS Act (00:30): Hear about options under consideration for PAMA reform, including the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.When cerebrospinal fluid (CSF) metagenomics benefit patient care (06:04): Explore how CSF metagenomics work and when it is appropriate to use this advanced diagnostic tool in clinical practice.Advancement and innovation in metagenomics (18:15): Discover how recent and upcoming innovation is expanding metagenomic testing capabilities. Note: Information in this post was accurate at the time of its posting.ResourcesAnswers From the Lab podcast: Developments for LDT Regulation and Laboratory Reimbursement: Bill Morice, M.D., Ph.D.Metagenomics: Identifying elusive pathogenic microorganisms

In this episode of Dominate Your Day, we delve into the inspiring stories of transformation and recovery through the Men of Nehemiah program. This unique initiative combines military discipline, faith-based discipleship, and clinical support to help men overcome addiction and rebuild their lives. We hear from Rand Carlson, a former participant who now serves as the Biblical Director, sharing his personal journey from addiction to leadership. Melinda Russ the Executive Director, discusses the program's holistic approach, emphasizing the importance of treating the whole person mind, body, and soul. Today's episode highlights the power of community involvement and mentorship, showcasing how these elements contribute to personal growth and well-being. Through heartfelt stories and testimonies, you will gain insight into the profound impact of the Men of Nehemiah, not only on the individuals involved but also on their families and the broader community. Our conversation underscores the message that recovery is a lifelong journey, and with the right support and dedication, transformation is possible for anyone. Episode Minutes: Minute 3: Personal Stories of Transformation Minute 9: The Role of Military Discipline Minute 15: Faith-Based Support Minute 21: Community and Mentorship Minute 27: Impact on Families and Communities To find out more about my work, please visit www.danawilliamsco.com LinkedIn Instagram My Book - The Internal Revolution: Lead Authentically and Build Your Personal Brand from Within Email: hello@danawilliamsco.com The Strengths Journal™ is the only Gallup-certified, purpose-driven daily planner that helps you actively use your strengths to plan your days. Get Your copy here

About Nikhil Buduma:Nikhil Buduma is a San Francisco–based entrepreneur, scientist, and engineer working at the cutting edge of AI and healthcare. He is the co-founder and CEO of Ambience Healthcare, an AI platform built to supercharge every healthcare worker with intelligent automation. Under his leadership, Ambience has grown into one of the most well-funded AI healthcare startups in the world, raising over $343 million from top investors, including a16z, OpenAI, Kleiner Perkins, Oak HC/FT, Optum Ventures, and industry pioneers such as Jeff Dean and Pieter Abbeel. Before becoming CEO, Nikhil served as Ambience's Chief Scientist, leading the development of its core AI systems that streamline documentation, coding, and clinical workflows for healthcare systems, including the Cleveland Clinic and St. Luke's.Prior to Ambience, Nikhil co-founded Remedy Health, where he applied machine learning to advance value-based care models, backed by Khosla Ventures and Greylock. He also co-founded Lean On Me, a nonprofit organization that supports mental health and wellness across U.S. college campuses through anonymous peer-to-peer text support networks at institutions such as MIT, Duke, and UC Berkeley.A graduate and valedictorian of Bellarmine College Preparatory, Nikhil earned both his bachelor's and master's degrees in computer science and engineering from MIT. His career reflects a rare blend of technical mastery, compassion, and vision—using AI not to replace clinicians, but to restore the human joy in the practice of medicine.Things You'll Learn:Health systems often see low real-world usage of ambient tools; when daily adoption crosses most clinicians and visits, the ROI conversation becomes meaningful. This requires solving fundamentals across specialties, not just shipping features.If AI generates notes that don't align with payer rules and codes, organizations incur rework and risk. Integrating HCC, ICD-10, and CPT selection, along with supporting language, at the point of care helps prevent denials.Revenue integrity upside: Bringing CDI intelligence forward can reclaim large sums from work already done but not credited. This strengthens both financial sustainability and compliance posture.Continuous third-party auditing and domain-specific modeling are essential because general reasoning models often struggle with the nuances of revenue cycles. Independent validation builds organizational trust.Patient Summary anticipates questions and data needs before the visit, while Chart Chat answers complex, EHR-aware queries in seconds, helping to democratize top-tier standards of care in rural settings.Resources:Connect with and follow Nikhil Buduma on LinkedIn.Follow Ambience Healthcare on LinkedIn and visit their website. 

Why is it that women experience stress more intensely than men? Drs. Daina Parent and Annette Schippel discuss the connection between women's hormones and the effects of stress on the female body. Dr. Schippel shares her personal and professional experience navigating the stages of a woman's reproductive journey and how endocrine health plays a significant role in hormone balance. Drs. Parent and Schipple emphasize the importance of working with qualified healthcare providers trained in herbal medicine in order to find the right herbs for each person and symptom picture. Dr. Schippel offers invaluable clinical tools and takeaways to create a strong foundation for any woman to navigate stress management and optimal wellness with nutrition, herbs, lifestyle and more. Dr. Annette Schippel is a chiropractor and a graduate of Logan College of Chiropractic, she brings over 25 years of experience to her work. She owns two thriving family practices that focus on pediatrics, women's health, and clinical nutrition, and she regularly sees patients from across the United States and around the world. Known for her expertise in functional medicine and endocrinology, Dr. Schippel has become a respected educator, author, and speaker. She has written and co-authored numerous clinician manuals and lectures domestically and internationally on topics in nutrition and functional endocrinology.  She has had the privilege of visiting Medi-Herb in Australia for 3 years to receive advanced training in phytotherapy.  She also had the honor to speak on alternative approaches to Metabolic Syndrome at the 2014 International Health Management Forum in Bejing China. Show Summary 2:24 Female hormones and stress sensitivity 4:00 The HPA Axis and the stress response 5:35 The thyroid adrenal connection 7:57 Cortisol, DHEA and the adrenal cortex 9:15 Prolactin, dopamine and high prevalence of autoimmunity in women 11:30 Key differences in male and female hormones: estradiol, testosterone, and DHEA 15:27 Peri- and menopausal hormone shifts 16:33 Adrenal burnout and perimenopause: the resiliency of the stress response affects hormone balance 21:13 Clinical strategies for adrenal support to mitigate perimenopausal symptoms – diet, exercise, sleep, digestion, and mental health 25:42 Herbs for adrenal support and endocrine balance – rehmania, ashwagandha, chaste tree, schizandra and more 29:33 How herbs modulate and synergize with hormones 30:02 Social media trends – perspectives on ashwagandha 33:06 Why guidance from a healthcare provider with herbal knowledge matters – finding the right herbs for each person 35:35 Choosing the right herb – how patient health history and symptom picture inform herbal selection 44:39 Using blood chemistry to inform patient protocols 45:55 Personalizing herbal protocols for different stages of the lifespan 48:38 Nutrients and herbs for libido and vaginal dryness and how adrenal resilience plays a role in these symptoms 50:32 Circulation, sexual health, and blood-flow support 52:53 Improving vasodilation through nitric oxide; whole foods and herbs that support circulation (beets, mountain spinach, red algae, and more) 54:45 Herbs as modulators – herbs won't increase or decrease hormones too much 55:16 The truth about wild yam creams 58:54 The practitioner-patient journey - navigating better health together 1:01:51 Key clinical takeaway for supporting women's health and stress management – how to build a good foundation and never lose sight of what you're trying to build

Half of students in public schools in the United States are low income. Also half are minorities. What are the challenges and what are the solutions to better educate these kids? Dick’s guest, Art Rainwater retired in 2008 after 10 years as Superintendent of Madison Metropolitan School District in Madison, Wisconsin. He is currently Clinical […]

De enorme hack bij laboratorium Clinical Diagnostics in de zomer 2025 zorgde voor bijna een miljoen gedupeerden. Persoonsgegevens zoals burgerservicenummers en adressen, medische uitslagen van Bevolkingsonderzoek Nederland en zelfs adressen van blijf-van-mijn-lijfhuizen werden gestolen. Het lijkt erop dat al die gevoelige informatie op één database stond, waardoor deze enorme hoeveelheid data in een keer te vinden viel. Het is een van de gevoelige punten in dit verhaal, want waarom zijn al die persoonlijke gegevens nog steeds aan elkaar gekoppeld? En waarom staat de gevoelige data van Bevolkingsonderzoek Nederland überhaupt op de database van Clinical Diagnostics, waar de beveiliging niet op orde blijkt te zijn? Het is immers niet meer de vraag óf je gehackt wordt, maar wanneer. De gevolgen van de hack bij Clinical Diagnostics gaan een stuk verder dan enkel het verkopen van mensen hun gebruikersnaam en wachtwoord. De verantwoordelijke Russische Nova Ransomwaregroep focust zich in eerste instantie puur op waar ze binnen kunnen komen. Pas toen de gestolen data een paar dagen op internet stond, bleek pas wat voor waardevols zij in handen hadden. De media reageerde, en de prijzen bij Nova gingen omhoog. Ben van der Burg en Mark Beekhuis nemen de de hack bij Clinical Diagnostics van begin tot nu onder de loep, met cybersecurity specialist Chantal Stekelenburg. Gast Chantal Stekelenburg Video Youtube Hosts Ben van der Burg & Mark Beekhuis Redactie Daniël Mol Rosanne PetersSee omnystudio.com/listener for privacy information.

In this episode of the Smarter Not Harder Podcast, the HOMeHOPe Faculty — Dr. Scott Sherr, Dr. Ted Achacoso, Dr. Jup Kuipers, and Dr. Allen Bookatz — reunite for a timely and insightful roundtable on play, presence, and practitioner power in the age of AI. From microdosing in medicine to using ChatGPT in clinical care, this conversation explores how fun, flow, and forward-thinking frameworks can reinvent healthcare from the inside out. Join us as we delve into: • How "play" transforms clinical performance, creativity, and resilience • The promise and pitfalls of AI like ChatGPT and Gemini in modern medicine • HOMeHOPe's model of proactive care — and why health optimization starts before symptoms • From burnout to breakthrough: how clinicians can reclaim joy and curiosity in practice This episode is for you if: • You're a clinician feeling trapped between protocols and possibility • You want to integrate fun, flow, and fulfillment into your professional life • You're curious about AI in healthcare — and how to use it responsibly • You're done with sick-care and ready to optimize health before disease strikes You can also find this episode on… Youtube: https://www.youtube.com/watch?v=gzgJ81OZ2lM Find more from Smarter Not Harder: Website: Smarter Not Harder Podcast Instagram: https://instagram.com/troscriptions/ HOMeHOPe Virtual Symposium 2026: https://homehope.org/homehope-virtual-symposium-2026 Get 10% Off your purchase of the Metabolomics Module by using PODCAST10 at https://www.homehope.org/ Get 10% Off your Troscriptions order with code POD10 at https://troscriptions.comGet daily content from the hosts of Smarter Not Harder by following @troscriptions on Instagram.

Join us on the latest episode, hosted by Jared S. Taylor!Our Guest: Yaw Fellin, Senior Vice President and GM, UpToDate Clinical Decision Support and Provider Solutions at Wolters Kluwer Health.What you'll get out of this episode:How UpToDate is making clinical decision support conversationalWhy validation, quality, and expert oversight are essential in AI toolsThe growing impact of workflow integration and ambient technologiesKey takeaways from HLTH 2025, including partnerships and customer momentumThe shift from AI hype to real-world clinical impactTo learn more about :Website https://www.wolterskluwer.com/en/health Linkedin https://www.linkedin.com/company/wolters-kluwer-health/Guest Linkedin https://www.linkedin.com/in/yaw-fellin-470a5621/Our sponsors for this episode are:Sage Growth Partners https://www.sage-growth.com/Quantum Health https://www.quantum-health.com/Show and Host's Socials:Slice of HealthcareLinkedIn: https://www.linkedin.com/company/sliceofhealthcare/Jared S TaylorLinkedIn: https://www.linkedin.com/in/jaredstaylor/WHAT IS SLICE OF HEALTHCARE?The go-to site for digital health executive/provider interviews, technology updates, and industry news. Listed to in 65+ countries.

Most employers are wasting money on "cost containment" solutions that nobody uses. They buy a 1-800 number or a wellness app, hoping for savings, but get zero engagement because employees don't trust a stranger at a call center. If your advocacy solution has no engagement, it has zero ROI. It's like playing slots in the "Healthcare Casino"—you keep putting money in, but the house always wins.Real ROI requires real trust. My guest, Matt McQuide of Synergy Healthcare, joins me on The Broker's Voice to break down the financial impact of Embedded Clinical Advocacy. We discuss why assigning a dedicated nurse to a specific client (not a random voice on a phone line) is the only way to drive the engagement necessary to redirect care and prevent catastrophic claims. This is the strategy for turning advocacy from a line item expense into a massive return on investment.▶▶ Sign Up For Your Free Discovery Callhttps://calendly.com/aneary/strategy-sessionCONNECT WITH ANDY NEARY

In this hot seat coaching conversation, Sarah Jabeen MD, a clinician turned medical writer, brings the honest questions so many emerging CME writers quietly carry:How do I navigate a career pivot without feeling like an imposter? How do I leverage my clinical background without overwhelming my writing? And how do I grow from “new” to “trusted” in the eyes of clients?Together, we unpack what's underneath each of these questions and explore how identity, confidence, community, and small experiments shape your growth as a CME writer.You'll hear:Why self-doubt is a normal part of professional transformation—and how to shift from “What if this fails?” to “What if this works?”How your clinical experience becomes a true superpower in CME writing, giving you insight, relevance, and empathy that elevate your work.What separates a beginner from a trusted partner, and how reliability, curiosity, and consistent communication matter more than perfection.The role of community and belonging in building confidence and combating isolation during a career pivot.Practical guidance for showing up online, finding your voice, and creating a presence that feels aligned and safe.Whether you're transitioning from clinical practice, entering CME writing from another discipline, or simply looking for more confidence in your craft, this episode offers permission, perspective, and a path forward.Mentioned in this episode:12 Days of GivingThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

The Centers for Disease Control and Prevention recently released its Core Elements of Hospital Diagnostic Excellence. Given the significant implications of diagnostic stewardship on the use of antimicrobials, US Antibiotic Awareness Week is an excellent opportunity to begin to unpack this topic. This podcast reviews the core elements and explores the opportunities for pharmacists to engage in diagnostic stewardship and how this topic has broader implications beyond antimicrobial use.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

This episode features hosts Zach and Kevin, who welcome returning guest Dr. Frank Clayton to discuss the psychology and process of retiring from dentistry. Dr. Frank Clayton, who sold his practice and fully exited clinical work in July 2023, shares his insightful journey and the various phases of retirement he's experienced, including the "honeymoon phase." Kevin, who recently sold his practice in August and is now navigating the associate phase, offers his perspective on the initial mental shifts of stepping away from ownership. The hosts and Frank delve into the factors that drive the decision to sell—a combination of financial goals, mental fatigue, and a desire to "go out on top." They discuss the emotional weight of a "two-year breakup" with patients and staff, the challenges of detaching from the owner's mindset, and the importance of a well-structured ramp-down, which for Frank, included cutting back income and clinical work months before his final day. Join the Very Clinical Facebook group!  Join the Very Dental Facebook group using the password "Timmerman," "Bioclear," Hornbrook," "Gary," "McWethy," "Papa Randy" or "Lipscomb!" The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code "VERYSHIP" you'll get free shipping on your order! Go save yourself some money and support the show all at the same time! The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!

For this week's episode of the Clinician's Corner, we've gone into the archives to pull out another clinical pearl from one of our favorite episodes - and today we discuss the powerful healing properties of sulforaphane with David Roberts & Dr. John Gildea, from Mara Labs.   This interview first aired in 2023, and the full interview can be viewed here.   Clinical pearls we extracted from the original interview: The story behind BrocElite, a stabilized sulforaphane supplement The motivation behind the research  The scientific background on sulforaphane (e.g., its development and stabilization) How sulforaphane plays a role in cancer and chemotherapy  The Clinician's Corner is brought to you by the Institute of Restorative Health. Follow us: https://www.instagram.com/instituteofrestorativehealth/   Connect with Mara Labs: Website: https://mara-labs.com/ Instagram: https://www.instagram.com/themaralabs/?hl=en Facebook: https://www.facebook.com/themaralabs/    Speaker bios: David Roberts holds a MPH from Johns Hopkins, a Masters in BME from the UVA, and a Bachelors in EE and BME from Duke. David has more than 20 years of public health experience on three continents. In 2014 David cofounded the gut supplement, RESTORE, now called ION.    Dr. John Gildea is Cell Pathophysiologist and Molecular Geneticist with 33 years of scientific research experience at the bench in both industrial and academic labs.  A guiding principle of his work is to establish innovative optimized model systems and assays in order to robustly investigate both normal and pathological states. He has extensive expertise establishing and investigating in-vivo, ex-vivo, primary and immortalized cell culture systems, molecular biology, antibody based and nucleic acid based diagnostic assay development, electron and fluorescence microscopy and flow cytometry. Dr. Gildea has published 63 peer reviewed articles, 3 book chapters, 3 reviews, 3 patents, and has 3173 citations.    Keywords: functional health, sulforaphane, broccoli, breast cancer, oncology, chemosensitizer, glucoraphanin, myrosinase, supplement, restorative health, anti cancer, clinical skills, chronic disease, cancer models, NRF2, antioxidant system, chemotherapy, metastasis, Mara Labs, Baroque Elite, broccoli sprouts, juicing, practitioner training, case studies, gastrointestinal healing, functional medicine, curriculum, certification, clinical mastery, immune system, detoxification Disclaimer: The views expressed in the IRH Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of the Institute of Restorative Health, LLC. The Institute of Restorative Health, LLC does not specifically endorse or approve of any of the information or opinions expressed in the IRH Clinician's Corner series. The information and opinions expressed in the IRH Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. The Institute of Restorative Health, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the IRH Clinician's Corner series. By viewing or listening to this information, you agree to hold the Institute of Restorative Health, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Frances Varian from the University of Sheffield, UK. They discuss her insights as a cardiologist and geography graduate working in the NHS with respect to the environmental impact of climate change on our health. Dr Varian is leading the British Cardiovascular Society's environment and sustainability committee. They also explore how cardiovascular care and research both have environmental impacts and what we can do individually and at a population level to reduce this impact. Please see the links below for more information.   If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us reach more people - thank you! Links: ESC strategic plan 2023-2028 (includes sustainability)  RCP green physicians toolkit Quantifying the carbon footprint of clinical trials  Clinical trials carbon footprint guidance Carbon footprint calculator (Travel) Food - BBC Climate Change food calculator

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251347539

Co-hosts Mike Mills and Mary Crowley-Farrell speak with Denyce Watts-Daniels, Associate Professor in Nursing at Coppin State about her use of Generative AI to create case studies relevant to her nursing students.

From horse tranquilizer to mental health treatment — what's the real story about ketamine? Nick Pell breaks it down on Skeptical Sunday!Welcome to Skeptical Sunday, a special edition of The Jordan Harbinger Show where Jordan and a guest break down a topic that you may have never thought about, open things up, and debunk common misconceptions. This time around, we're joined by writer and researcher Nick Pell!Full show notes and resources can be found here: jordanharbinger.com/1241On This Week's Skeptical Sunday:Ketamine therapy shows promise for treatment-resistant depression, PTSD, and chronic pain, but it's serious medicine requiring proper medical supervision, not a recreational escape or wellness trend.Clinical ketamine treatment involves IV administration with precise dosing, vital monitoring, and trained medical attendants — drastically different from recreational use that can cause severe bladder damage and other complications.The rise of telehealth ketamine clinics and mail-order treatments represents a concerning trend — proper vetting requires full psych evaluations, bloodwork, and screening by legitimate medical professionals, not vague promises.Recreational ketamine use carries significant addiction potential and health risks, particularly bladder damage from chronic high doses — clinical settings minimize these dangers through controlled administration.If you're considering ketamine therapy, start with a therapist and real medical doctor. Look for evidence-based treatment with proper intake procedures, not spa-like "optimization centers" making grandiose claims.Connect with Jordan on Twitter, Instagram, and YouTube. If you have something you'd like us to tackle here on Skeptical Sunday, drop Jordan a line at jordan@jordanharbinger.com and let him know!And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors: The Cybersecurity Tapes: Listen here: thecybersecuritytapes.comBiOptimizers: 25% off November 23rd to December 3rd: bioptimizers.com/jordan, code JORDANHomes.com: Find your home: homes.comShopify: 3 months @ $1/month (select plans): shopify.com/jordanApretude: Learn more: Apretude.com or call 1-888-240-0340See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello record from the ASTMH meeting in Toronto and discuss continuing avian flu outbreaks, the continued global measles outbreak, the effectiveness of high and low doses of the influenza vaccine before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, children hospitalizations following COVID-19 and influenza vaccination, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Five new avian flu outbreaks confirmed in ducks, turkeys in 3 US states (CIDRAP) Confirmation of highly pathogenic Avian Influenza in Commercial and Backyard flocks (USDA: Animal and Plant Health Inspection Service) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD) (LANCET) Relative effectiveness of the high-dose versus standard-dose influenza vaccines for the prevention of laboratory-confirmed influenza among Italian older adults during three recent seasons (International Journal of Infectious Diseases) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-word global database (Journal of Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) COVID-19 and influenza deaths in Australian children 2018-2023: a national case analysis (Journal of Pediatric Infectious Diseases Society) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1270 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

This episode recorded live at the 10th Annual Health IT + Digital Health + RCM Annual Meeting features Ginny Torno, Senior Director, Innovation & IT Clinical Systems at Houston Methodist, sharing how Houston Methodist leverages AI to improve patient outcomes, enhance operational efficiency, and support clinicians while emphasizing strong governance, ROI, and change management in technology adoption.

The Cost of Caring with Ona Clark – Client Desires, Therapist Boundaries - Erotic Transference Explored In Episode 355 of the Counselling Tutor Podcast, your hosts Rory Lees-Oakes and Ken Kelly take us through this week's three topics: Firstly, in ‘Ethical, Sustainable Practice', they discuss the importance of having a clinical will - why it matters, what it should include, and how it upholds your ethical responsibilities. Then in ‘Practice Matters', Rory speaks with Ona Clark about the cost of caring - highlighting the emotional, financial, and systemic barriers that many face when training to become a counsellor. And finally, in ‘Student Services', Rory and Ken explore erotic transference - how to recognise it, work with it ethically, and maintain clear professional boundaries. The Importance of a Clinical Will [starts at 03:36 mins] In this section, Rory and Ken unpack the ethical and legal reasons for having a clinical will and how it ensures continuity of care for clients. Key points discussed include: A clinical will ensures that clients are treated ethically and professionally in the event of a therapist's death or incapacitation. Ethical frameworks now state that therapists should have a clinical will - it's no longer optional. The document designates an executor (often a peer or supervisor) who can securely manage client data and provide closure for clients. Therapists must include clear details about client records, contracts, supervision, and how information is stored and accessed. Loved ones and supervisors should be informed of the will's existence and who the executor is. Clinical wills uphold confidentiality, legal compliance, and demonstrate professional responsibility. The Cost of Caring with Ona Clark [starts at 34:07 mins] In this week's ‘Practice Matters', Rory speaks with neurodivergent counsellor and advocate Ona Clark, who shares her personal and professional reflections on the hidden costs of becoming a therapist. Key points from this conversation include: Training to become a counsellor carries hidden financial burdens - from personal therapy and unpaid placements, to travel and supervision. These costs disproportionately affect students from lower-income and underrepresented backgrounds. Ona highlights the additional emotional labour experienced by Black and minoritised trainees, often working harder to feel seen and heard. Mental health impacts of financial strain include burnout, anxiety, and difficulty engaging in personal development. Greater funding, policy reform, and access to therapy for counsellors are needed to build a more inclusive profession. Ona's campaign “The Cost of Caring” calls for structural change - raising awareness and seeking support through petition and advocacy. Ona also writes thoughtfully about the experiences of survivors in her article, Beyond the Silence: 8 Things Survivors Need from Counsellors — exploring how therapists can create spaces of safety, empathy, and understanding in their work. Plus, she is featured in the latest issue of the National Counselling & Psychotherapy Society (NCPS) magazine, where she expands on themes of neurodivergence, grief support and mental-health advocacy. Client Desires, Therapist Boundaries – Erotic Transference Explored [starts at 58:35 mins] In this section, Rory and Ken explore the complex phenomenon of erotic transference and how therapists can respond ethically and professionally. Key points include: Erotic transference refers to romantic or sexual feelings a client may develop toward their therapist - often rooted in earlier attachment patterns or unmet emotional needs such as validation or closeness. The term was coined by Sigmund Freud in the early 20th century (c. 1912–1915), who described it as Übertragungsliebe - a sexualised form of transference not to be gratified, but analysed within therapy.

Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics:  Introduction: About This Program (0:00) Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10) Potential Treatment Benefits of CAR T-Cell Therapy (10:35) CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32) Finding Information About CAR T; Clinical Trials (42:17) Financial Issues; Risk of Infection (48:11) Coping with Anxiety; Healing and Moving On (55:17) Educational and presenter information

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

Ibrahim Nawaz Khan joins Ethics Talk to discuss his article, coauthored with Dr Lauren Smith: "What Are Ethical Merits and Drawbacks of a Patient's Open and Direct Access to Clinical Information in Their EHRs During a Hospital Stay?"  Recorded July 30, 2025.  Read the full article for free at JournalOfEthics.org

This episode guides pharmacists through the essentials of pediatric primary and secondary survey assessment, common etiologies of pediatric cardiopulmonary arrest, pediatric advanced life support algorithms for dysrythmias, and provide useful medication tips and management considerations for the clinical pharmacist. CE for this episode expires on November 15, 2027.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This accredited continuing education program is supported by an educational grant from Sanofi. Credit for the program can be obtained by visiting https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-cidp/ . This program, led by Jeffrey Allen, MD, Professor of Neurology at the University of Minnesota provides an overview on the diagnostic delays that often occur in patients with CIDP as well as best practices to suspect and diagnose this rare condition more efficiently. This activity has been designed to meet the educational needs of physicians specializing in family medicine, pediatrics, and neurology. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the early symptoms of CIDP.List best practices which can be used to diagnose CIDP more efficiently.Faculty Jeffrey Allen, MDProfessor of NeurologyDepartment of NeurologyDivision of Neuromuscular MedicineUniversity of MinnesotaMinneapolis, MNDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses Consultant/Educational talks: Annexon, Alexion, Amgen, CSL Behring, Takeda,BioCryst, Grifols, Argenx, Sanofi, Immunovant, ImmunoAbs, Octapharma, Alnylam, AstraZeneca, Dianthus, Johnson & Johnson, Laboratoire Français du Fractionnement et des Biotechnologies, Nuvig, Akcea Therapeutics, ImmunoPharma,Pfizer.Community Faculty/Patient (Christine Eleeson): No relevant financial relationships with any ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre-and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This week on A Week In Her Wallet, we head to Atlanta to follow Kristen, a 40-something clinical researcher who earns about $150K a year and travels nearly full-time for work. She walks us through a week of thoughtful spending, including a $1,300 mortgage payment, $500 toward her HELOC, a $150 yard sale win (promptly spent on music festival tickets), and the small joys that keep her grounded when she's on the road so much.

John Murray, Ali Bruce-Ball & Conor McNamara talk football, travel & language after Cristiano Ronaldo sees red as Republic of Ireland beat Portugal, and England beat Serbia. What about the ‘mind-altering' shoes some of the England players are wearing? There's a European theme to Clash of the Commentators. And suggestions always welcome for our Great Glossary of Football Commentary and unintended pub names from football commentary - WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk00:40 Conor fresh from Ireland-Portugal 04:40 Takeaways from England-Serbia 06:05 Mind-altering shoes & commentary attire 16:05 5 Live commentaries this weekend 18:00 John prepares for trip to Albania 24:55 Unintended (and intended) pub names 33:15 Clash of the Commentators 41:45 Great Glossary of Football Commentary 52:55 Magazine memories5 Live / BBC Sounds Premier League commentaries: Fri 1945 Slovakia v Northern Ireland on Sports Extra, Sat 1330 Man City v Man Utd in WSL on Sports Extra, Sat 1700 Liechtenstein v Wales on Sports Extra, Sat 1945 Greece v Scotland on 5 Live, Sun 1200 Liverpool v Chelsea in WSL on Sports Extra, Sun 1200 Brighton v Leicester in WSL on Sports Extra 2, Sun 1430 Tottenham v Arsenal in WSL on 5 Live, Sun 1700 Albania v England on 5 Live, Mon 1945 Northern Ireland v Luxembourg on Sports Extra, Tue 1945 Scotland v Denmark on 5 Live, Tue 1945 Wales v North Macedonia on Sports Extra, Wed 2000 Arsenal v Real Madrid in UWCL on 5 Live, Thu 2000 Chelsea v Barcelona in UWCL on 5 Live.Glossary so far (in alphabetical order):DIVISION ONE Bosman, Cruyff Turn, Dead-ball specialist, Fox in the box, Giving the goalkeeper the eyes, Head tennis, Hibs it, In a good moment, Leading the line The Maradona, Olimpico, Onion bag, Panenka, Rabona, Scorpion kick, Spursy, Tiki-taka, Where the kookaburra sleeps, Where the owl sleeps, Where the spiders sleep.DIVISION TWO Ball stays hit, Business end, Came down with snow on it, Cauldron atmosphere Coat is on a shoogly peg, Come back to haunt them, Easy tap-in, Daisycutter, First cab off the rank, Has that in his locker, High wide and not very handsome, Howler, One for the cameras, One for the purists, Played us off the park, Purple patch, Put their laces through it, Rolls Royce, Root and branch review, Row Z, Seats on the plane, Show across the bows, Stramash, Taking one for the team, That's great… (football), Thunderous strike.UNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Bread and butter, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Nutmeg, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.

In this episode, Jason Keeler, President of ReloShare Medical Respite and former COO at UCMC, discusses how early lung nodule detection and collaborative leadership between clinical and administrative teams can improve patient outcomes, streamline care pathways, and strengthen the financial health of healthcare organizations.This episode is sponsored by Noah Medical.

In this episode of MyHeart.net, cardiologist Dr. Alan Bouchard sits down with Dr. Timothy Garvey, Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham, to discuss the evolving definition of obesity as a disease. Drawing from The Lancet's 2025 clinical framework, Dr. Garvey explains when excess adiposity begins to impair organ function, how this redefinition changes patient care, and why understanding obesity as a chronic disease is essential for preventing cardiometabolic complications.About the TeamDr. Alain Bouchard is a clinical cardiologist at Cardiology Specialists of Birmingham, AL. He is a native of Quebec, Canada and trained in Internal Medicine at McGill University in Montreal. He continued as a Research Fellow at the Montreal Heart Institute. He did a clinical cardiology fellowship at the University of California in San Francisco. He joined the faculty at the University of Alabama Birmingham from 1986 to 1990. He worked at CardiologyPC and Baptist Medical Center at Princeton from 1990-2019. He is now part of the Cardiology Specialists of Birmingham at UAB Medicine.Dr. Philip Johnson is originally from Selma, AL. Philip began his studies at Vanderbilt University in Nashville, TN, where he double majored in Biomedical and Electrical Engineering. After a year in the “real world” working for his father as a machine design engineer, he went to graduate school at UAB in Birmingham, AL, where he completed a Masters and PhD in Biomedical Engineering before becoming a research assistant professor in Biomedical Engineering. After a short stint in academics, he continued his education at UAB in Medical School, Internal Medicine Residency, and is currently a cardiology fellow in training with a special interest in cardiac electrophysiology.Medical DisclaimerThe contents of the MyHeart.net podcast, including as textual content, graphical content, images, and any other content contained in the Podcast (“Content”) are purely for informational purposes. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on the Podcast!If you think you may have a medical emergency, call your doctor or 911 immediately. MyHeart.net does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Podcast. Reliance on any information provided by MyHeart.net, MyHeart.net employees, others appearing on the Podcast at the invitation of MyHeart.net, or other visitors to the Podcast is solely at your own risk.The Podcast and the Content are provided on an “as is” basis.

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical psychologist Adia Gooden and NPR's It's Been A Minute host, Brittany Luse, answer questions from Dear Life Kit listeners and they share their best advice on unsolicited advice.Follow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekitLearn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this episode of WDx, Cheryl, Kaylin, and Sharmin are joined by Kuchal and Ann Marie, two wonderful members of the CPSolvers Academy.  Kuchal presents a case of a young man with fevers to Ann Marie and Sharmin. Download CPSolvers App here RLRCPSOLVERS

In this episode, ARK's Cathie Wood and Brett Winton sit down with Sean McClain, Founder and CEO of AbSci, to explore how generative AI is reshaping drug discovery, development timelines, and clinical costs. Sean walks through real-world examples of AI-designed antibodies—such as AbSci's breakthrough HIV antibody and a regenerative treatment for hair loss—and explains how these platforms are helping unlock previously “undruggable” biology.They discuss AbSci's Phase 2-ready hair growth antibody (BS201), the company's partnerships with Caltech and AMD, and why the FDA's evolving embrace of AI could accelerate the end of animal testing. The conversation closes with a forward-looking discussion on the role of regenerative medicine in longevity—and why AI drug discovery might just pull biotech out of its multi-year bear market.Key Points From This Episode:(00:00:00) How AbSci uses generative AI to design antibodies from scratch(00:02:42) HIV, ion channels, and the promise of targeting "undruggable" biology(00:06:28) AbSci's BS201 drug for hair regrowth: mechanism, speed, and cost advantages(00:13:20) Clinical timeline: From concept to Phase 2 readout in 3.5 years(00:15:34) Bringing costs down: $100–150M vs. the industry average of $2.4B(00:17:36) Why AI enables “keys designed for specific locks” in drug targeting(00:22:58) What AbSci's models are trained on—and how prompts work in drug inference(00:25:32) The future of clinical testing: AI replacing animal models(00:36:43) Sarcopenia, strength loss, and regenerative approaches to aging(00:48:10) BS201 as a long-acting pulse therapy—and how it compares to transplants

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Ever threaten to take away screen time… only to hand the iPad back 10 minutes later just so you can finish your coffee in peace?

Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients. Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed: • The importance of comprehensive next-generation sequencing (NGS) in management of NSCLC. • A detailed overview of ROS1 TKIs, including crizotinib, repotrectinib, entrectinib, taletrectinib. • Common side effects associated with these agents, such as fatigue, dizziness, edema, and liver toxicity. • Clinical pearls for managing adverse events and optimizing patient care. • The significance of patient education and regular follow-ups in ensuring treatment adherence and safety. Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into the practical aspects of treating ROS1 fusion positive NSCLC. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other ToxCheck episodes, conference highlights, and treatment algorithms. Subscribe for more discussions on bridging the gap between academic research and community practice! #ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer

Every few years, conversations about education in the U.S. circle back to the same refrain: Why can't we be more like Finland?In this episode, I sit down with Dr. Chrishawn Finister from Your Joy Psychological, PLLC to unpack this comparison.We dig into the nuanced relationship between educational eligibility and clinical diagnosis, which often overlap but aren't interchangeable. From there, we widen the lens to explore the broader systems-level challenges that shape how students are identified, supported, and served.Some key themes we discuss:✅ Orthographic density and literacy: Why differences in written language systems matter when comparing reading outcomes across countries.✅ Population homogeneity and “education tracks”: When we look at instructional outcomes data, the students included in the education system and the numbers matter. Are the same individuals “counting” when we compare results across countries? ✅ Teacher pay and professional identity: What Finland's investment in teacher preparation and salary looks like compared to the U.S. (spoiler alert: Dr. Finister and I both think the US should be more like Finland on this one). ✅ Cultural perceptions of medicine vs. education: Why recommendations from evaluations are perceived differently depending on the setting and who is making decisions about services.✅ Housing instability and socioeconomic factors: We're educating students with complex needs in the US who have varying experiences outside of school. With this in mind, has the education system made more progress than what the media is saying? Rather than looking for a one-size-fits-all solution, we highlight why U.S. educators, policymakers, and clinicians need to understand the challenges and opportunities when designing systems of support.If you've ever wondered where the lines between clinical diagnosis and educational eligibility blur, this conversation will give you a grounded perspective.Dr. Chrishawn Finister is an Independent Practicing Licensed Psychological Associate and a Licensed Specialist in School Psychology, possessing over a decade of experience in the role of School Psychologist. Recognized as a Nationally Certified School Psychologist, she is committed to utilizing diagnostically sound assessments to identify learning barriers and implementing research-based interventions to amend challenging behaviors effectively. Dr. Finister is an advocate of culturally competent practices and is dedicated to training future practitioners in the field. She received her foundational training in psychological pedagogy and assessments at Texas Woman's University, where she completed her Master's degree in 2010. While working in a prominent North Texas public school district, she advanced her education by earning a Doctoral degree in Educational Leadership and Policy from the University of Texas at Arlington in 2019. Her contributions to the field extend to academia, where she has served as a guest lecturer at the College of Education at Texas Christian University.Places to connect with Dr. Finister:Her private practice, Your Joy Psychological, PLLCWebsite: https://yourjoypsych.com/Business Instagram: @yourjoypsychHer NonProfit, Texas Psychological Hive: https://thetexaspsychhive.org/Non-profit Instagram: @texaxpsychhiveAdditional Resources Mentioned in this episode:Steven Pinker: https://stevenpinker.com/Mark Manson: https://markmanson.net/Dr. Tim Shanahan: https://www.shanahanonliteracy.com/In this episode, I mention Language Therapy Advance Foundations, my program that gives SLPs and other service providers a system for language therapy. You can learn more about the program here: https://drkarenspeech.com/languagetherapy/ We're thrilled to be sponsored by IXL. IXL's comprehensive teaching and learning platform for math, language arts, science, and social studies is accelerating achievement in 95 of the top 100 U.S. school districts. Loved by teachers and backed by independent research from Johns Hopkins University, IXL can help you do the following and more:Simplify and streamline technologySave teachers' timeReliably meet Tier 1 standardsImprove student performance on state assessments

Clinical psychologist Dr. Genesee Herzberg joins Kyle to reflect on two decades in trauma work and 15 years inside the psychedelic ecosystem—from early MAPS conferences to running Sage Integrative Health. She traces how personal psychedelic experiences set her on a path of service, research at CIIS on MDMA-assisted therapy, and hands-on roles with MAPS: Zendo Project harm reduction, adherence rating, and ultimately serving as an MDMA therapist in clinical trials. Today she leads Sage, an integrative clinic (psychotherapy, psychiatry, bodywork, acupuncture, and functional nutrition) focused on ketamine-assisted therapy while preparing for MDMA's eventual approval. She also co-founded a sliding-scale KAP nonprofit (now Alchemy Community Therapy Center), co-edited Integral Psychedelic Therapy, and is helping to launch the International Alliance of MDMA Practitioners. In this episode From counterculture to mainstream: What's been gained—and lost—as psychedelics scaled. Accessibility vs. corporatization: Why cutting corners (prep/integration, therapeutic time) undermines outcomes and safety. "Myth of the magic pill": Psychedelics can catalyze change, but healing is an ongoing process anchored by integration. What good care looks like: Preparation → medicine sessions → robust integration, individualized cadence, and adding bodywork and functional medicine to address gut-brain links, mineral status, sleep, and somatic tension. Ketamine realities: Differences between psycholytic (talk-forward) and psychedelic (eyes-closed, inner-directed) dosing; why some need multiple sessions to build relationship with the medicine; risks of mail-order models (high dosing, poor screening/support), daily prescribing, addiction potential, cystitis, and safety concerns. Sitting, not guiding: The therapist's task is to follow the client's process; intervene sparingly and with consent—especially in trauma work where attuned co-regulation is essential. Multiple access pathways: Support for regulated clinical care and community, peer, and ceremonial models—paired with education and harm reduction (Zendo's SIT peer training and new crisis-responder training). The MDMA pause: Initial devastation at the FDA decision gave way to seeing benefits: time to strengthen ethics, accountability, training standards, and to temper hype-driven investment. Pace and ethics: Lessons from burnout; moving at the speed of trust; exploring "psychedelic business models" (stakeholder focus, distributed decision-making, employee ownership, public benefit structures). Resources & organizations mentioned Sage Integrative Health Alchemy Community Therapy Center (sliding-scale KAP) International Alliance of MDMA Practitioners Integral Psychedelic Therapy (edited by Genesee Herzberg, Jason Butler, Richard Miller) Takeaway: Thoughtful preparation, right-sized dosing, and committed integration—held within ethical, community-minded systems—turn powerful experiences into durable change.

Hosts Zach and Kevin put the sports talk (mostly) aside to dive deep into a critical area of everyday dentistry: various scenarios involving soft and hard tissue grafting and the management of periodontal recession. They discuss how to handle common cases like recession in post-ortho teens (especially on the lower anterior teeth) and the different approaches for the challenging chewing tobacco patient. Zach and Kevin share their experience with generalized recession, debating when to refer for a graft—often noting that patient concern over esthetics or sensitivity drives the decision more than the presence of the recession itself. The conversation covers treatment techniques like free gingival grafts and the status of fads like the LANAP procedure and pinhole technique. They also explore other periodontal topics, including the management of gingival overgrowth (gummy smiles), peri-implantitis complications, and their skepticism regarding the widespread use of local antimicrobial delivery systems (like Arrestin) for routine scaling and root planing cases. Tune in for a candid discussion on what's working (and what's not) in the everyday management of periodontal health in a general practice. Join the Very Clinical Facebook group!  Join the Very Dental Facebook group using the password "Timmerman," "Bioclear," "Hornbrook," McWethy," "Papa Randy," "Lipscomb" or "Gary!" The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! -- Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code "VERYDENTAL10" you'll get another 10% off your order! Go save yourself some money and support the show all at the same time! -- The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! -- Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! -- CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!  

Do This NOW: The 1-Minute Technique to Drop Anxiety & Regulate Your Nervous SystemYour Instant 60-Second Vagus Nerve ResetFeeling a flash of anxiety, emotional overwhelm, or stuck in a loop of overthinking? This short, powerful 1-minute guided session is your immediate tool for nervous system reset and fast stress relief.Clinical hypnotherapist Martin from Calming Anxiety guides you through a simple, yet highly effective somatic technique that takes just 60 seconds to perform.What You Will Learn in 1 Minute:How to use a long, slow out breath (a sighing breath) to speak directly to your vagus nerve.A powerful method to immediately signal safety to your mind.How to feel your core regulate and release built-in tension.This is the perfect emotional regulation tool to use instantly at your desk, before a difficult conversation, or any time you need to drop anxiety fast and carry calm into the next hour.For Deeper Calm: If you need deeper somatic healing or more extended emotional regulation tools, subscribe to Calming Anxiety.Support the Show:Ad-Free Listening: Enjoy Calming Anxiety without ads at https://www.spreaker.com/podcast/calming-anxiety--4110266/supportBuy Me a Coffee: Support hosting costs at https://www.buymeacoffee.com/calminganxietyRate & Review: Leave a 5-star review on Spotify or Apple Podcasts to help us reach more listeners!Resources & Courses:Book Hypnotherapy: Schedule a one-on-one session with Martin at https://calendar.app.google/rXHMt8sRYft5iWma8 Pain & Anxiety Course:Manage negative thoughts and pain with The Physio Crew's course at https://offers.thephysiocrew.co.uk/home-painBreathing Challenge: Try our relaxing breathing challenge at https://www.martinhewlett.co.uk/breathing-challenge/Gift a Subscription: Share Calming Anxiety with loved ones at https://www.martinhewlett.co.uk/shop/calming-anxiety-gift-subscription/Get the App:iOS: Download Calming Anxiety at https://apps.apple.com/gb/app/calming-anxiety/id1576159331 Android:Get it on Google Play at https://play.google.com/store/apps/details?id=digital.waterfront.calming.anxiety&hl=en-GBConnect With Us:Email: Share feedback or requests at calminganxiety@martinhewlett.co.ukYouTube: Watch all episodes at https://www.youtube.com/c/calminganxiety?sub_confirmation=1 Social Media Support: For younger listeners struggling with social media stress, visit https://www.icanhelp.net/Backing Music: Chris Collins===================Affiliate links to the gear I use the items that give me a more tranquil life.Rode Podmic - https://amzn.to/3LN1JEdZoom Livetrak L8 - https://amzn.to/36UCIbySony ZV 1 - https://amzn.to/3JvDUPTGoPro Hero 8 Black - https://amzn.to/372rzFlDJI Mini 2 - https://amzn.to/3NQfMdY=============================Items I use for a more relaxed way of life :)Organic Pure Hemp CBD Capsules - https://amzn.to/3Ready for More Calm?Thank you for listening to the Calming Anxiety Podcast, featuring guided meditation, mindfulness, and sleep hypnosis sessions with Martin Hewlett. Our mission is to provide you with proven tools for anxiety relief, stress reduction, and a path toward deep relaxation. Use this episode anytime you need to calm your mind and feel more at ease.

Join George Hariri and Richard Low as they dive into the real-world applications of AI in dental practice management. From co-diagnosis tools and automated SOP creation to marketing insights and team performance reviews, they explore how dentists can harness AI today—and what's just around the corner.